135 related articles for article (PubMed ID: 34022457)
1. Off-on-off-on use of imatinib in three children with fibrodysplasia ossificans progressiva.
Kaplan FS; Teachey DT; Andolina JR; Siegel DM; Mancilla EE; Hsiao EC; Al Mukaddam M; Rocke DM; Pignolo RJ
Bone; 2021 Sep; 150():116016. PubMed ID: 34022457
[TBL] [Abstract][Full Text] [Related]
2. Early clinical observations on the use of imatinib mesylate in FOP: A report of seven cases.
Kaplan FS; Andolina JR; Adamson PC; Teachey DT; Finklestein JZ; Ebb DH; Whitehead B; Jacobs B; Siegel DM; Keen R; Hsiao E; Pignolo RJ
Bone; 2018 Apr; 109():276-280. PubMed ID: 28736245
[TBL] [Abstract][Full Text] [Related]
3. Acute and chronic rapamycin use in patients with Fibrodysplasia Ossificans Progressiva: A report of two cases.
Kaplan FS; Zeitlin L; Dunn SP; Benor S; Hagin D; Al Mukaddam M; Pignolo RJ
Bone; 2018 Apr; 109():281-284. PubMed ID: 29241828
[TBL] [Abstract][Full Text] [Related]
4. The Natural History of Flare-Ups in Fibrodysplasia Ossificans Progressiva (FOP): A Comprehensive Global Assessment.
Pignolo RJ; Bedford-Gay C; Liljesthröm M; Durbin-Johnson BP; Shore EM; Rocke DM; Kaplan FS
J Bone Miner Res; 2016 Mar; 31(3):650-6. PubMed ID: 27025942
[TBL] [Abstract][Full Text] [Related]
5. Longitudinal patient-reported mobility assessment in fibrodysplasia ossificans progressiva (FOP).
Kaplan FS; Al Mukaddam M; Pignolo RJ
Bone; 2018 Apr; 109():158-161. PubMed ID: 28600150
[TBL] [Abstract][Full Text] [Related]
6. Depletion of Mast Cells and Macrophages Impairs Heterotopic Ossification in an Acvr1
Convente MR; Chakkalakal SA; Yang E; Caron RJ; Zhang D; Kambayashi T; Kaplan FS; Shore EM
J Bone Miner Res; 2018 Feb; 33(2):269-282. PubMed ID: 28986986
[TBL] [Abstract][Full Text] [Related]
7. Imaging assessment of fibrodysplasia ossificans progressiva: Qualitative, quantitative and questionable.
Al Mukaddam M; Rajapakse CS; Pignolo RJ; Kaplan FS; Smith SE
Bone; 2018 Apr; 109():147-152. PubMed ID: 28822792
[TBL] [Abstract][Full Text] [Related]
8. Acute unilateral hip pain in fibrodysplasia ossificans progressiva (FOP).
Kaplan FS; Al Mukaddam M; Pignolo RJ
Bone; 2018 Apr; 109():115-119. PubMed ID: 28822791
[TBL] [Abstract][Full Text] [Related]
9. Study methodology and insights from the palovarotene clinical development program in fibrodysplasia ossificans progressiva.
Pignolo RJ; Al Mukaddam M; Baujat G; Brown MA; De Cunto C; Hsiao EC; Keen R; Le Quan Sang KH; Grogan DR; Marino R; Strahs AR; Kaplan FS
BMC Med Res Methodol; 2023 Nov; 23(1):269. PubMed ID: 37957586
[TBL] [Abstract][Full Text] [Related]
10. An mTOR Signaling Modulator Suppressed Heterotopic Ossification of Fibrodysplasia Ossificans Progressiva.
Hino K; Zhao C; Horigome K; Nishio M; Okanishi Y; Nagata S; Komura S; Yamada Y; Toguchida J; Ohta A; Ikeya M
Stem Cell Reports; 2018 Nov; 11(5):1106-1119. PubMed ID: 30392977
[TBL] [Abstract][Full Text] [Related]
11. "I Can't Take off My Shirt or Do My Own Hair"-A Qualitative Investigation of the Symptoms and Impact Experience of Children and Adolescents with Fibrodysplasia Ossificans Progressiva (FOP).
Markowitz JT; Rofail D; Vandenberg G; Baldasaro J; Sanchez RJ; Pignolo RJ; Keen R; Davis M; Marquis P
Adv Ther; 2022 Jun; 39(6):2796-2805. PubMed ID: 35429282
[TBL] [Abstract][Full Text] [Related]
12. Surgical management of bilateral hip fractures in a patient with fibrodysplasia ossificans progressiva treated with the RAR-γ agonist palovarotene: a case report.
Singh S; Kidane J; Wentworth KL; Motamedi D; Morshed S; Schober AE; Hsiao EC
BMC Musculoskelet Disord; 2020 Apr; 21(1):204. PubMed ID: 32245464
[TBL] [Abstract][Full Text] [Related]
13. A cumulative analogue joint involvement scale (CAJIS) for fibrodysplasia ossificans progressiva (FOP).
Kaplan FS; Al Mukaddam M; Pignolo RJ
Bone; 2017 Aug; 101():123-128. PubMed ID: 28465250
[TBL] [Abstract][Full Text] [Related]
14. Fibrodysplasia ossificans progressiva: Review and research activities in Japan.
Haga N; Nakashima Y; Kitoh H; Kamizono J; Katagiri T; Saijo H; Tsukamoto S; Shinoda Y; Sawada R; Nakahara Y
Pediatr Int; 2020 Jan; 62(1):3-13. PubMed ID: 31774601
[TBL] [Abstract][Full Text] [Related]
15. Skeletal malformations and developmental arthropathy in individuals who have fibrodysplasia ossificans progressiva.
Towler OW; Shore EM; Kaplan FS
Bone; 2020 Jan; 130():115116. PubMed ID: 31655222
[TBL] [Abstract][Full Text] [Related]
16. International physician survey on management of FOP: a modified Delphi study.
Di Rocco M; Baujat G; Bertamino M; Brown M; De Cunto CL; Delai PLR; Eekhoff EMW; Haga N; Hsiao E; Keen R; Morhart R; Pignolo RJ; Kaplan FS
Orphanet J Rare Dis; 2017 Jun; 12(1):110. PubMed ID: 28606101
[TBL] [Abstract][Full Text] [Related]
17. Mast cell inhibition as a therapeutic approach in fibrodysplasia ossificans progressiva (FOP).
Brennan TA; Lindborg CM; Bergbauer CR; Wang H; Kaplan FS; Pignolo RJ
Bone; 2018 Apr; 109():259-266. PubMed ID: 28851540
[TBL] [Abstract][Full Text] [Related]
18. Palovarotene Inhibits Heterotopic Ossification and Maintains Limb Mobility and Growth in Mice With the Human ACVR1(R206H) Fibrodysplasia Ossificans Progressiva (FOP) Mutation.
Chakkalakal SA; Uchibe K; Convente MR; Zhang D; Economides AN; Kaplan FS; Pacifici M; Iwamoto M; Shore EM
J Bone Miner Res; 2016 Sep; 31(9):1666-75. PubMed ID: 26896819
[TBL] [Abstract][Full Text] [Related]
19. Activin A amplifies dysregulated BMP signaling and induces chondro-osseous differentiation of primary connective tissue progenitor cells in patients with fibrodysplasia ossificans progressiva (FOP).
Wang H; Shore EM; Pignolo RJ; Kaplan FS
Bone; 2018 Apr; 109():218-224. PubMed ID: 29170109
[TBL] [Abstract][Full Text] [Related]
20. Prevalence of fibrodysplasia ossificans progressiva (FOP) in the United States: estimate from three treatment centers and a patient organization.
Pignolo RJ; Hsiao EC; Baujat G; Lapidus D; Sherman A; Kaplan FS
Orphanet J Rare Dis; 2021 Aug; 16(1):350. PubMed ID: 34353327
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
